Dec
08
MedQIA is announcing today the approval of its DHHS 501(k) application for integrated image analysis and data analysis system, known as IBIS: Imaging Biomarker Information System. IBIS provides data storage with full audit time stamp and e-signature capabilities. The IBIS system was developed specifically for use in clinical trials. The resulting affects include the lowest adjudication rates in the industry. This adjudication rate derives from the unique computer-aided approach to tumor contouring and measurement implemented in the IBIS Markup package. The IBIS Explorer and Markup Software are in fact two distinct pieces of technology, IBIS Explorer stores and displays the images; the Markup Software is used to measure specified regions on the images, interpret results and generate reports based on those results. In addition to the software’s core capabilities IBIS provides a number of clinical application including; oncology and lesion marking and analysis, and anatomic structure marking, volume measurement and analysis. The system is able to perform analysis on multiple modality data sets including Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Bone Scan, Positron Emission Tomography (PET) – CT, and Ultrasound.
In Clinical Trials, from preclinical to phase 3 registration trials, IBIS allows for multiple reader paradigms with full regulatory compliance at each step. The unique system allows for selection and follow up of both target and non-target lesions, while allowing for full independence of the read with respect to lesion selection and contour validation. The integration of the measurements and radiologist’s opinions which are also captured electronically into the database allow for rapid data turnaround and validation and start- up deliverable times to sponsors.
About MedQIA
MedQIA is unique as an imaging CRO that focuses on the development, validation and implementation of novel imaging biomarkers. MedQIA provides end-to-end capabilities in image data collection, quality control and advanced quantitative analyses. Our integration of optimized standardized image acquisition across multicenter clinical trial sites, with advanced image analysis tools using IBIS allows us to be a one-stop resource for imaging challenges in clinical trials. Key differentiators that MedQIA provides include rigorous management of the imaging aspects of the clinical protocol, as well as rapid Quality Control feedback to the clinical site. This results in maximum value for the dollars invested in the imaging components of a study protocol.
Contacts
Juliette Bridges
310-481-7561
jbridges@medqia.com
Matthew Brown, PhD
310-794-8969
mbrown@medqia.com
Jonathon Goldin, MD, PhD
310-481-7570
jgoldin@medqia.com
Dec
08
click here to view poster
San Antonio Breast Cancer Symposium: December 6-10, 2011
Henry B. Gonzalez Convention Center, San Antonio, Texas, USA
Dec
08
“Very importantly in this investigator-sponsored trial, we used a prospectively defined definition of bone scan response using central review of bone scans in the computer assisted quantitative measurement by MedQIA. As you see here all of the patients had improvements in bone lesion area, 10 of the 11 patients met criteria for response with greater than 30% improvement in bone lesion area and again at 40 milligram. Those results prompted us to look at lower doses, we saw less activity at 20 milligrams and they are now withstanding the cohort at 40 milligrams and as of yesterday accrued the last patient to that study.”
“Now with a word about this method of bone scan assessment, again this is done by a company called MedQIA. It is computer assisted, and it is objective, highly reproducible and quantifiable. We are very intrigued by this again impressed with its utility in evaluation in investigator-sponsored trial, but of course, we are starting at, we will require prospective clinical validation and it’s our intention to do that in a subsequent larger study.”
Dec
08
“CADrx for GBM Brain Tumors: Predicting Treatment Response from Changes in Diffusion-Weighted MRI”
Authors: Jing Huo, Matthew Brown, Kazanuri Okada For details of the book see: http://www.igi-global.com/book/machine-learning-computer-aided-diagnosis/56023
Nov
14
Come visit Dr. Matt Brown’s Poster presentation “Cabozantinib effects on bone metastasis: Computer-aided quantitative bone scan assessment of prostate cancer treatment response” Monday Nov. 14th at the 2011 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference in San Francisco, California
Session ID: Poster Session B
Session Title: Imaging
Session Date and Time: Monday Nov 14, 2011 12:30 PM – 2:30 PM
Location: West Hall, Level One, Moscone Center West
Permanent Abstract Number: B114
Click here to view the poster
Oct
27
Dr. Matt Brown will be presenting the following poster presentation:
Cabozantinib effects on bone metastasis: Computer-aided quantitative bone scan assessment of prostate cancer treatment response
It will also be published in the 2011 Conference Program and Proceedings. Presentation information:
Session ID: Poster Session B
Session Title: Imaging
Session Date and Time: Monday Nov 14, 2011 12:30 PM – 2:30 PM
Location: West Hall, Level One, Moscone Center West
Permanent Abstract Number: B114
Nov
17
Authors: Matthew Brown, Fereidoun Abtin, Hyun J Kim, Michael McNitt-Gray & Jonathan Goldin
Publication: Imaging Med. (2010)2(5), 563-573
Please contact MedQIA if you would like a copy of this article
Emphysema is a disease that causes destruction of lung tissue and an overall reduction in lung compliance
as air becomes trapped in the diseased regions. It affects an estimated 60 million people worldwide and
up to 2 million Americans. As the disease progresses, the hyperinflated regions continue to expand, limiting
the effective volume available for more viable lung tissue. New biomedical valves and stents are being
developed that can be implanted in target airways to allow air to escape from the most diseased lung
lobe, thereby reducing its volume and providing more space for the adjacent (healthier) lobe to expand.
The challenge facing the clinician is to determine which patients are most likely to benefit from the
treatment and which lobe/airway should be treated. This article describes imaging biomarkers and an
automated computer-aided diagnosis system to perform patient selection and treatment targeting
in emphysema.
Emphysema is a disease that causes destruction of lung tissue and an overall reduction in lung compliance
as air becomes trapped in the diseased regions. It affects an estimated 60 million people worldwide and
up to 2 million Americans. As the disease progresses, the hyperinflated regions continue to expand, limiting
the effective volume available for more viable lung tissue. New biomedical valves and stents are being
developed that can be implanted in target airways to allow air to escape from the most diseased lung
lobe, thereby reducing its volume and providing more space for the adjacent (healthier) lobe to expand.
The challenge facing the clinician is to determine which patients are most likely to benefit from the
treatment and which lobe/airway should be treated. This article describes imaging biomarkers and an
automated computer-aided diagnosis system to perform patient selection and treatment targeting
in emphysema.
Executive summary
Executive summary
Executive summary
Sep
27
Frank C. Sciurba, M.D., Armin Ernst, M.D., Felix J.F. Herth, M.D., Charlie Strange, M.D., Gerard J. Criner, M.D., Charles H. Marquette, M.D., Ph.D., Kevin L. Kovitz, M.D., M.B.A., Richard P. Chiacchierini, Ph.D., Jonathan Goldin, M.D., Ph.D., and Geoffrey McLennan, M.D., Ph.D. for the VENT Study Research Group
N Engl J Med 2010; 363:1233-1244September 23, 2010
Background
Endobronchial valves that allow air to escape from a pulmonary lobe but not enter it can induce a reduction in lobar volume that may thereby improve lung function and exercise tolerance in patients with pulmonary hyperinflation related to advanced emphysema.
Methods
We compared the safety and efficacy of endobronchial-valve therapy in patients with heterogeneous emphysema versus standard medical care. Efficacy end points were percent changes in the forced expiratory volume in 1 second (FEV1) and the 6-minute walk test on intention-to-treat analysis. We assessed safety on the basis of the rate of a composite of six major complications.
Results
Of 321 enrolled patients, 220 were randomly assigned to receive endobronchial valves (EBV group) and 101 to receive standard medical care (control group). At 6 months, there was an increase of 4.3% in the FEV1 in the EBV group (an increase of 1.0 percentage point in the percent of the predicted value), as compared with a decrease of 2.5% in the control group (a decrease of 0.9 percentage point in the percent of the predicted value). Thus, there was a mean between-group difference of 6.8% in the FEV1 (P=0.005). Roughly similar between-group differences were observed for the 6-minute walk test. At 12 months, the rate of the complications composite was 10.3% in the EBV group versus 4.6% in the control group (P=0.17). At 90 days, in the EBV group, as compared with the control group, there were increased rates of exacerbation of chronic obstructive pulmonary disease (COPD) requiring hospitalization (7.9% vs. 1.1%, P=0.03) and hemoptysis (6.1% vs. 0%, P=0.01). The rate of pneumonia in the target lobe in the EBV group was 4.2% at 12 months. Greater radiographic evidence of emphysema heterogeneity and fissure completeness was associated with an enhanced response to treatment.
Conclusions
Endobronchial-valve treatment for advanced heterogeneous emphysema induced modest improvements in lung function, exercise tolerance, and symptoms at the cost of more frequent exacerbations of COPD, pneumonia, and hemoptysis after implantation. (Funded by Pulmonx; ClinicalTrials.gov number, NCT00129584.)
Aug
10
This edition of the International Workshop on Pulmonary Image Analysis brings together researchers in pulmonary image analysis to discuss recent advances in this rapidly developing field. Many imaging modalities are currently available to study the lungs, including radiography, CT, PET and PET/CT, MRI and more. We invite papers that deal with all aspects of image analysis of pulmonary image data, including segmentation, registration, quantification, computer-aided detection and diagnosis of lung disease, modeling of the image acquisition process, visualization, statistical modeling, biophysical modeling of the lungs (computational anatomy), lung image analysis in animals, and novel applications.
Apr
14
Come see us at the Annual Society of Clinical Oncologists (ASCO) Annual Meeting June 5 – 8 in Chicago. We are in booth # 20144
|
